Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

High Hopes For Stent Antiplatelet Therapy Trial

This article was originally published in The Gray Sheet

Executive Summary

FDA, along with the four major drug-eluting stent manufacturers and four antiplatelet drug firms, are months away from launching an unprecedented $100 million, 20,000-patient trial to determine the optimum duration of dual antiplatelet therapy with drug-eluting stents
Advertisement

Related Content

FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
Industry Post-Stenting Antiplatelet Trial Gains $1.5 Million Boost From FDA
Major Trials On Dual-Antiplatelet Therapy For DES In The Works
Confusion Over Anti-Clotting Therapy Hinders Drug-Eluting Stent Rebound
Confusion Over Anti-Clotting Therapy Hinders Drug-Eluting Stent Rebound
Advertisement
UsernamePublicRestriction

Register

MT026694

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel